Ask every provider the same questions.
Record whether 24/7 on-site physician coverage, ECG capability, transfer planning, assessment protocols, exclusion criteria, and follow-up are documented in the same terms for each profile.
Canada · provider due diligence
Provider Comparison Matrix
A neutral, repeatable way to build a comparative profile of individual Canadian ibogaine providers without endorsing any clinic.
A working standard
Compare evidence, not impressions.
Ibogaine care can involve serious medical risk. A comparison matrix should therefore record what a provider can show, explain, and verify—not what a website promises or what a single anecdote suggests. Begin with the safety-focused questions in the Canadian ibogaine care overview, then give every provider the same fields and the same opportunity to clarify their answers.
Use this page as a durable template. It is not a ranking, certification, or referral tool. It is a way to separate documented practice from unavailable information, and to retain uncertainty where the evidence does not support a conclusion.
Three comparison principles
A matrix is only as careful as its rules.
Set the standard before reviewing any provider. This keeps the record consistent and reduces the risk that presentation, price, or proximity is mistaken for evidence of safety.
Keep a source beside each answer.
Distinguish a written policy, direct written response, public record, or independent documentation from a broad marketing statement. Date each entry and retain the original context.
Leave gaps visible.
“Not provided” is a useful finding. Do not turn absent documentation into an assumption that a practice is in place, and do not convert a completed matrix into a recommendation.
Verification record
Build a file that another careful reader can inspect.
For each field, preserve the question asked, the date, the exact response, and the source type. When a provider describes cardiac screening or monitoring, ask what is available on site, who interprets it, and what happens if a concern is identified. The Health Canada drug product database is one official place to check product information where a specific authorized product is claimed.
Product claims deserve their own evidence column. Ask for GMP or pharmacy documentation where applicable, along with the name of the product form and the limits of what can be verified. A plain-language ibogaine HCl guide can help distinguish product terminology, but it cannot establish a particular provider’s supply chain or clinical safeguards.
For wider context, compare the provider’s stated model with the questions in the clinic comparison guide. The aim is consistency: a claim should be recorded at the level of proof actually available.
Core fields
Use measurable fields, then state the evidence level.
The fields below are intended to make meaningful differences visible. A provider may supply more detail; record it without treating it as proof unless there is a source you can retain and review.
| Field | What to record | How to verify |
|---|---|---|
| Medical presence | Whether an on-site physician is available 24/7 during treatment, and how coverage is described. | Request a written description of the role, coverage period, escalation pathway, and any limits. |
| Cardiac monitoring | ECG screening and monitoring capability, including timing and response procedures. | Ask for the assessment and monitoring protocol rather than relying on a general statement about safety. |
| Emergency transfer | Named transfer process, destination planning where disclosed, transport arrangements, and estimated transfer time. | Request the written emergency plan and distinguish a stated relationship from a documented transfer arrangement. |
| Product documentation | GMP, pharmacy, or other supply documentation stated for the product used. | Ask what document can be reviewed, who issued it, and what product it covers. |
| Pre-treatment assessment | Medical history, medication review, cardiac assessment, informed consent, and timing of screening. | Request the current intake or assessment protocol with personal details removed. |
| Exclusion criteria | Conditions, medications, or circumstances that lead to deferral or exclusion. | Ask for written criteria and whether they are reviewed by a qualified clinician. |
| Aftercare and reporting | Post-discharge follow-up, adverse-event reporting process, and what transparency is offered. | Request the follow-up schedule and a description of how adverse events are documented and communicated. |
Scoring and collection
Score the evidence state—not the person.
A simple four-state system is often more honest than a single numerical score: documented and independently verifiable; documented but not independently verifiable; stated without documentation; or unavailable/not applicable. Keep the descriptive notes alongside the state so a reader can see why it was assigned.
Where information is public, capture the publication date and preserve a copy or citation. Where information is not public, request permission before publishing a provider response. For records held by public institutions, an access-to-information or freedom-of-information route may be relevant where applicable; the Government of Canada’s access to information guidance explains the federal framework, while provincial processes differ.
When reviewing the legal and regulatory context, do not assume that a provider statement resolves it. The question of whether ibogaine is illegal in the United States illustrates why jurisdiction and regulatory category should be recorded separately from a provider’s operating claims. For background on the substance itself, the general reference entry on ibogaine is useful for orientation, not for judging a particular provider.
“A comparison matrix should make uncertainty legible. It should never turn incomplete evidence into a seal of approval.”
Ethics and interpretation
Questions that protect the record.
Should a matrix rank providers from best to worst?
No. A single ranking can hide important differences and imply a recommendation that the evidence does not justify. Keep individual fields visible instead. This is especially important when comparing different care settings, including descriptions of ibogaine detox centers or facilities promoted through location-specific pages such as an ibogaine clinic in Tijuana.
Can patient stories be used as proof?
Patient accounts may identify questions to ask, but they should not be republished as verification without informed consent and corroborating documentation. Avoid publishing private health information, identifying details, or unverified anecdotes. A claim about trauma-related care should be approached with the same restraint whether it appears in material about ibogaine for PTSD treatment or therapy approaches for PTSD.
How should cost information appear in a comparison?
Record the date, currency, inclusions, exclusions, refund terms, and whether a figure is a quote or a published price. Do not compare bare totals across jurisdictions. Context from an ibogaine cost overview and discussion of the cost of ibogaine treatment in Mexico can help frame questions, but neither establishes the value or safety of a Canadian provider.
What should happen when no evidence is available?
Mark the field as unavailable and explain what was requested. Do not fill the gap with assumptions. Cross-border comparisons can be particularly difficult: material on ibogaine treatment centers in Europe may describe different rules and care pathways. Understanding how ibogaine works may inform the questions, but it does not verify any provider’s practice.
A careful next step
Keep the questions clear. Keep the evidence attached.
Use the matrix alongside independent background material on the psychedelic drug ibogaine and the approach outlined in our decision-support materials. Neither replaces medical or legal advice, and neither endorses a provider.
Review regulatory and safety questions